Principal Financial Group Inc. decreased its position in shares of Cantel Medical Corp. (NYSE:CMD) by 2.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 274,227 shares of the company’s stock after selling 7,122 shares during the period. Principal Financial Group Inc. owned approximately 0.66% of Cantel Medical worth $25,823,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Globeflex Capital L P bought a new position in Cantel Medical in the second quarter worth approximately $114,000. LS Investment Advisors LLC purchased a new position in Cantel Medical in the second quarter worth $172,000. Airain ltd purchased a new position in Cantel Medical in the second quarter worth $201,000. Punch & Associates Investment Management Inc. purchased a new position in Cantel Medical in the second quarter worth $212,000. Finally, Riverhead Capital Management LLC purchased a new position in Cantel Medical in the second quarter worth $218,000. 84.98% of the stock is owned by institutional investors and hedge funds.
Cantel Medical Corp. (NYSE CMD) traded down $0.28 during trading hours on Wednesday, hitting $100.21. 257,963 shares of the company were exchanged, compared to its average volume of 146,503. The stock has a market cap of $4,321.89, a PE ratio of 49.70 and a beta of 1.24. Cantel Medical Corp. has a 1 year low of $69.21 and a 1 year high of $108.00. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.41 and a quick ratio of 1.49.
Cantel Medical (NYSE:CMD) last released its earnings results on Thursday, September 28th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.02. Cantel Medical had a net margin of 9.27% and a return on equity of 17.60%. The company had revenue of $205.50 million for the quarter, compared to analyst estimates of $200.32 million. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. equities analysts predict that Cantel Medical Corp. will post 2.34 earnings per share for the current year.
The business also recently declared a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Investors of record on Wednesday, January 17th will be paid a dividend of $0.085 per share. This is a positive change from Cantel Medical’s previous Semi-Annual dividend of $0.07. This represents a yield of 0.17%. The ex-dividend date is Tuesday, January 16th. Cantel Medical’s dividend payout ratio (DPR) is currently 8.19%.
CMD has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Cantel Medical from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Cantel Medical in a research report on Friday, September 1st. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Cantel Medical has a consensus rating of “Hold” and an average target price of $91.67.
In other Cantel Medical news, Director George L. Fotiades sold 6,000 shares of Cantel Medical stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $95.23, for a total transaction of $571,380.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Charles M. Diker sold 20,500 shares of Cantel Medical stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $99.15, for a total transaction of $2,032,575.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,368 shares of company stock worth $3,576,028 over the last quarter. 12.30% of the stock is owned by company insiders.
Cantel Medical Company Profile
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.